{"product_id":"post-neoadjuvant-treatment-for-early-breast-cancer-what-happens-when-cancer-remains-after-chemotherapy","title":"Post-Neoadjuvant Treatment for Early Breast Cancer: What Happens When Cancer Remains After Chemotherapy?","description":"\u003cp\u003ePatients with early breast cancer who still have tumor remaining after chemotherapy given before surgery (neoadjuvant chemotherapy) face a higher risk of the cancer returning. A new review brings together every major clinical trial testing extra treatment given after surgery in this \"post-neoadjuvant\" setting. Two drugs are already standard: capecitabine for triple-negative breast cancer and T-DM1 (trastuzumab emtansine) for HER2-positive disease. Three newer options have joined them — the immune checkpoint inhibitor pembrolizumab, the PARP inhibitor olaparib and the CDK 4\/6 inhibitor abemaciclib — and more than 20 further trials are under way.\u003c\/p\u003e\n\n\u003ch1\u003ePost-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Treatment After Pre-Surgery Chemotherapy Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#terms\"\u003eKey Terms Explained\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#response\"\u003eHow Often Does Treatment Clear the Tumor? Rates by Cancer Subtype\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#tnbc\"\u003eTriple-Negative Breast Cancer: Chemotherapy, Targeted Drugs and Immunotherapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#her2\"\u003eHER2-Positive Breast Cancer: T-DM1 and Beyond\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#hr\"\u003eHormone Receptor-Positive, HER2-Negative Breast Cancer: CDK 4\/6 Inhibitors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#trials\"\u003eOngoing Clinical Trials: What Is Being Tested Now\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings at a Glance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Research Cannot Tell Us\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Practical Advice\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePatients with residual disease after chemotherapy before surgery have a higher risk of the cancer returning; those who reach pCR have lower recurrence and death rates.\u003c\/li\u003e\n\u003cli\u003eCapecitabine is standard for triple-negative breast cancer with residual disease; in CREATE-X's 286-patient triple-negative subgroup, it improved 5-year disease-free and overall survival.\u003c\/li\u003e\n\u003cli\u003eT-DM1 is standard for HER2-positive residual disease; in KATHERINE's 1,486 patients, 3-year invasive disease-free survival was 88.3% versus 77.0% with trastuzumab.\u003c\/li\u003e\n\u003cli\u003eOne year of olaparib may be recommended for patients with germline BRCA mutations and high recurrence risk, based on a 3.4 percentage point absolute improvement in 4-year overall survival.\u003c\/li\u003e\n\u003cli\u003eMore than twenty ongoing trials are testing new drugs, combinations and ctDNA-guided strategies; ask your oncology team whether you are eligible for one.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Treatment After Pre-Surgery Chemotherapy Matters\u003c\/h2\u003e\n\n\u003cp\u003eBreast cancer is the most common cancer in women worldwide. More than \u003cstrong\u003e450,000 new cases\u003c\/strong\u003e are diagnosed every year in Europe alone. Most patients — about \u003cstrong\u003e65%\u003c\/strong\u003e — are diagnosed when the disease is still early-stage, which means it can potentially be cured with standard local treatments (surgery and radiotherapy) and systemic treatments (drugs that travel through the bloodstream).\u003c\/p\u003e\n\n\u003cp\u003eEven so, up to \u003cstrong\u003e30%\u003c\/strong\u003e of patients experience the cancer coming back after surgery. The return can be local (near the original site) or distant (metastases, meaning spread to other organs).\u003c\/p\u003e\n\n\u003cp\u003eChemotherapy given before surgery is called \u003cstrong\u003eneoadjuvant chemotherapy (NAC)\u003c\/strong\u003e. It was first used for tumors that could not be removed by surgery, for locally advanced disease, or for inflammatory breast cancer. Today it is standard care for many forms of early breast cancer. The review lists three main reasons why doctors now use chemotherapy before rather than after surgery:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eIt may \u003cstrong\u003eshrink the tumor\u003c\/strong\u003e (a process called downstaging), leading to better surgical results with less extensive breast surgery and less extensive removal of underarm lymph nodes (axillary surgery).\u003c\/li\u003e\n  \u003cli\u003eIt lets doctors \u003cstrong\u003etest how well new drugs work in a living patient\u003c\/strong\u003e by watching tumor size change during treatment.\u003c\/li\u003e\n  \u003cli\u003eIt allows doctors to \u003cstrong\u003eincrease or decrease\u003c\/strong\u003e further drug treatment depending on how the tumor responded.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe largest evidence for this approach comes from a meta-analysis by the Collaborative Trials in Neoadjuvant Breast Cancer group. A meta-analysis is a study that pools results from many trials. The group was led by Cortazar and colleagues. That analysis included \u003cstrong\u003e11,955 patients\u003c\/strong\u003e. It found that patients who achieved a pathological complete response after neoadjuvant chemotherapy had better long-term survival than patients with leftover tumor. The link was even stronger in the more aggressive cancer subtypes — triple-negative breast cancer (TNBC) and HER2-positive, hormone receptor-negative tumors.\u003c\/p\u003e\n\n\u003cp\u003eThis creates two very different groups of patients after surgery. Patients whose tumor has disappeared may be candidates for \u003cstrong\u003ede-escalation\u003c\/strong\u003e (reducing treatment). Patients with tumor still present are at higher risk and may benefit from \u003cstrong\u003eadditional treatment after the neoadjuvant phase\u003c\/strong\u003e — the focus of this review.\u003c\/p\u003e\n\n\u003ch2 id=\"terms\"\u003eKey Terms Explained\u003c\/h2\u003e\n\n\u003cp\u003eUnderstanding the review requires a few definitions. Each term below is used repeatedly in the studies described.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathological complete response (pCR)\u003c\/strong\u003e — no detectable invasive cancer cells found in the tissue removed at surgery. Patients who reach pCR have a lower risk of the cancer returning.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResidual disease (RD)\u003c\/strong\u003e — cancer cells still present in the surgical specimen.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdjuvant treatment\u003c\/strong\u003e — treatment given after surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePost-neoadjuvant setting\u003c\/strong\u003e — the window after neoadjuvant therapy and surgery, when extra treatment may be given to patients with residual disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHazard ratio (HR)\u003c\/strong\u003e — a number comparing risk between two groups. An HR below 1.0 means the treatment group did better. For example, an HR of 0.50 means the risk of an event was cut roughly in half.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResidual Cancer Burden (RCB) index\u003c\/strong\u003e — a scoring system that combines measurements of the main tumor (its size and how densely packed with cancer cells it is) and lymph node metastases (how many nodes are involved and how large the deposits are). It sorts specimens into four classes: \u003cstrong\u003eRCB 0\u003c\/strong\u003e (which is the same as pCR), \u003cstrong\u003eRCB I\u003c\/strong\u003e, \u003cstrong\u003eRCB II\u003c\/strong\u003e and \u003cstrong\u003eRCB III\u003c\/strong\u003e. A higher RCB score means more residual disease and a higher risk of recurrence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe review also notes that residual disease can be assessed using various biomarkers for risk evaluation. Biomarkers are biological measurements. These biomarkers include Ki67, a marker of how fast cells divide. They also include TILs, which are tumor-infiltrating lymphocytes, immune cells found inside the tumor. Other biomarkers are the RCB index, gene expression patterns and genetic alterations.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a narrative review — a structured summary of existing evidence rather than a new experiment. The authors searched major scientific databases, including PubMed, along with conference proceedings from the main oncology conferences.\u003c\/p\u003e\n\n\u003cp\u003eThe search covered data available up to \u003cstrong\u003e1 August 2022\u003c\/strong\u003e. The review describes two categories of treatment: strategies already approved for clinical use, and strategies still under investigation in clinical trials. The authors include summary tables of completed practice-changing trials and of ongoing phase II and phase III studies.\u003c\/p\u003e\n\n\u003ch2 id=\"response\"\u003eHow Often Does Treatment Clear the Tumor? Rates by Cancer Subtype\u003c\/h2\u003e\n\n\u003cp\u003eThe likelihood of reaching pCR after neoadjuvant therapy differs sharply by cancer subtype. Understanding these numbers helps explain why some patients need more treatment after surgery and others may need less.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHormone receptor-positive, HER2-negative (HR+\/HER2−)\u003c\/strong\u003e is the most common subtype, occurring in about \u003cstrong\u003e70%\u003c\/strong\u003e of patients. Its pCR rate is the lowest: \u003cstrong\u003e8.3%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHER2-positive and hormone receptor-positive (HER2+\/HR+)\u003c\/strong\u003e accounts for roughly 20% of cases overall. Its pCR rate is \u003cstrong\u003e18.7%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHER2-positive and hormone receptor-negative (HER2+\/HR−)\u003c\/strong\u003e has a pCR rate of \u003cstrong\u003e38.9%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTriple-negative breast cancer (TNBC)\u003c\/strong\u003e occurs in about \u003cstrong\u003e10%\u003c\/strong\u003e of patients and has a pCR rate of \u003cstrong\u003e31.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese figures come from a meta-analysis by Houssami and colleagues published in the European Journal of Cancer in 2012. The pattern is clear: the more aggressive subtypes respond better to chemotherapy in terms of clearing the tumor. But the patients who do not reach pCR in those subtypes are the ones at highest risk of relapse.\u003c\/p\u003e\n\n\u003ch2 id=\"tnbc\"\u003eTriple-Negative Breast Cancer: Chemotherapy, Targeted Drugs and Immunotherapy\u003c\/h2\u003e\n\n\u003cp\u003eTNBC is an aggressive subtype of breast cancer with limited treatment options. Neoadjuvant combination chemotherapy remains the standard of care for early-stage TNBC larger than 2 cm or with positive lymph nodes.\u003c\/p\u003e\n\n\u003cp\u003eOnly rare histological subtypes — such as secretory or adenoid cystic carcinomas, which carry a low risk of recurrence — or very early-stage tumors classified as T1aN0 may avoid chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003epCR rates in TNBC have improved steadily over the past decades thanks to new treatment strategies. Two additions stand out:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eAdding \u003cstrong\u003ecarboplatin\u003c\/strong\u003e to the neoadjuvant regimen significantly improved pCR rates: \u003cstrong\u003e37%\u003c\/strong\u003e with a regimen not containing carboplatin versus \u003cstrong\u003e52%\u003c\/strong\u003e with one containing carboplatin.\u003c\/li\u003e\n  \u003cli\u003eAdding \u003cstrong\u003epembrolizumab\u003c\/strong\u003e (an immune checkpoint inhibitor) to neoadjuvant chemotherapy pushed the pCR rate as high as \u003cstrong\u003e65%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite these improvements, a substantial proportion of patients with TNBC still do not reach pCR after finishing neoadjuvant chemotherapy, and those patients face a higher risk of relapse. Several drugs have therefore been tested in the post-neoadjuvant setting.\u003c\/p\u003e\n\n\u003ch3\u003eCapecitabine: The First Approved Post-Neoadjuvant Treatment\u003c\/h3\u003e\n\n\u003cp\u003eThe CREATE-X trial was the first phase III study to show a benefit from giving extra capecitabine (an oral chemotherapy drug) after neoadjuvant chemotherapy was completed. In this trial, \u003cstrong\u003e910 patients\u003c\/strong\u003e with HER2-negative disease and residual tumor after neoadjuvant chemotherapy with anthracyclines and taxanes were randomly assigned to either observation (no further treatment) or six to eight cycles of adjuvant capecitabine.\u003c\/p\u003e\n\n\u003cp\u003eBoth disease-free survival and overall survival were significantly better in the capecitabine group, and the benefit was especially strong in the TNBC subgroup. Here are the detailed results:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAll HER2-negative patients (910):\u003c\/strong\u003e 5-year disease-free survival \u003cstrong\u003e74.1% with capecitabine versus 67.6% with no adjuvant therapy\u003c\/strong\u003e (HR 0.70); 5-year overall survival \u003cstrong\u003e89.2% versus 83.6%\u003c\/strong\u003e (HR 0.59).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTNBC subgroup (286 patients):\u003c\/strong\u003e 5-year disease-free survival \u003cstrong\u003e69.8% versus 56.1%\u003c\/strong\u003e (HR 0.58, 95% confidence interval 0.39–0.87); 5-year overall survival \u003cstrong\u003e78.8% versus 70.3%\u003c\/strong\u003e (HR 0.52, 95% CI 0.30–0.90).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInvasive disease-free survival in the overall population (1,836 patients):\u003c\/strong\u003e 4-year rate \u003cstrong\u003e82.7% versus 75.4%\u003c\/strong\u003e (HR 0.63).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePost-neoadjuvant capecitabine is now the standard of care for patients with TNBC who have residual disease after completing neoadjuvant chemotherapy.\u003c\/p\u003e\n\n\u003ch3\u003eOlaparib for Patients with Inherited BRCA Mutations\u003c\/h3\u003e\n\n\u003cp\u003eAmong patients with TNBC, those carrying germline (inherited) BRCA1 or BRCA2 mutations form a distinct high-risk subgroup. The OlympiA trial tested one year of oral olaparib in patients with high-risk HER2-negative early breast cancer and a germline BRCA mutation. Olaparib is a PARP inhibitor, a drug that blocks a DNA repair enzyme cancer cells depend on. Olaparib was given either after surgery or after neoadjuvant treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe second prespecified analysis of overall survival showed 4-year survival rates of \u003cstrong\u003e89.8% with olaparib versus 86.4% with placebo\u003c\/strong\u003e. That is an absolute improvement of \u003cstrong\u003e3.4 percentage points\u003c\/strong\u003e (HR 0.68, 98.5% CI 0.47–0.97; p=0.009).\u003c\/p\u003e\n\n\u003cp\u003eThe updated invasive disease-free survival and distant disease-free survival results matched earlier findings. Both favoured olaparib:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eInvasive disease-free survival: HR \u003cstrong\u003e0.63\u003c\/strong\u003e (95% CI 0.50–0.78).\u003c\/li\u003e\n  \u003cli\u003eDistant disease-free survival: HR \u003cstrong\u003e0.61\u003c\/strong\u003e (95% CI 0.48–0.77).\u003c\/li\u003e\n  \u003cli\u003e3-year distant disease-free survival in the HER2-negative\/TNBC group (1,509 patients): \u003cstrong\u003e86.5% with olaparib versus 79.1% with placebo\u003c\/strong\u003e (HR 0.61).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eApproaches That Did Not Work\u003c\/h3\u003e\n\n\u003cp\u003eNot every strategy tested has succeeded, and the review documents these negative results clearly.\u003c\/p\u003e\n\n\u003cp\u003eIn the BRE12-158 trial, residual tumors after neoadjuvant chemotherapy were sequenced using a next-generation sequencing assay (a test that reads the tumor's genetic code). Patients were then randomly assigned to four cycles of genomically targeted therapy — treatment matched to the specific mutations found — versus the treatment of the physician's choice. The study \u003cstrong\u003efailed to demonstrate\u003c\/strong\u003e that personalised therapy was superior to standard therapy.\u003c\/p\u003e\n\n\u003cp\u003eA subsequent phase III trial by the ECOG-ACRIN group tested post-neoadjuvant carboplatin or cisplatin against capecitabine in TNBC patients with residual disease. This trial also \u003cstrong\u003efailed to show superiority\u003c\/strong\u003e of the platinum drugs. In fact, the numbers favoured capecitabine: 3-year invasive disease-free survival was \u003cstrong\u003e42.8% with platinum versus 53.5% with capecitabine\u003c\/strong\u003e (HR 1.16, meaning a higher risk of events with platinum).\u003c\/p\u003e\n\n\u003ch3\u003eImmunotherapy in Early TNBC\u003c\/h3\u003e\n\n\u003cp\u003eImmunotherapy has transformed the treatment of several cancer types, including breast cancer. Several clinical trials in early TNBC have shown improvements in pCR rates when immunotherapy is added to standard chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKEYNOTE-522\u003c\/strong\u003e evaluated adding pembrolizumab to neoadjuvant chemotherapy with carboplatin and paclitaxel, followed by doxorubicin-cyclophosphamide, in patients with stage II–III TNBC (1,174 patients enrolled).\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003epCR rate: \u003cstrong\u003e64.8% with pembrolizumab versus 51.2% without\u003c\/strong\u003e (95% CI 5.4–21.8; p\u0026lt;0.001), which was the study's primary endpoint.\u003c\/li\u003e\n  \u003cli\u003eEstimated event-free survival at 36 months: \u003cstrong\u003e84.5% in the pembrolizumab group versus 76.8% in the standard group\u003c\/strong\u003e (HR 0.63, 95% CI 0.48–0.82; p\u0026lt;0.001) — an absolute improvement of \u003cstrong\u003e7.7 percentage points\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBased on these results, the U.S. Food and Drug Administration approved pembrolizumab in combination with neoadjuvant chemotherapy, followed by pembrolizumab alone as adjuvant treatment, for high-risk early-stage TNBC. Notably, this is the only trial that included a platinum drug in the chemotherapy backbone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIMpassion031\u003c\/strong\u003e was also conducted in stage II–III TNBC (455 patients), but used a different immune checkpoint inhibitor, atezolizumab, with nab-paclitaxel and no carboplatin in the neoadjuvant phase. Atezolizumab was continued for one year after surgery. The addition of atezolizumab produced a statistically significant increase in pCR rate: \u003cstrong\u003e57.6% versus 41.1%\u003c\/strong\u003e (95% CI 5.9–27.1; p=0.0044). However, the trial was not designed, or not \"powered\", to evaluate event-free survival, disease-free survival or overall survival. Those results are still immature. The median values have not been reached for any of these endpoints.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGepar-Nuevo\u003c\/strong\u003e tested a third immune checkpoint inhibitor, durvalumab, together with nab-paclitaxel followed by standard anthracycline-based chemotherapy in TNBC patients. The trial did not meet its primary endpoint of improving pCR. Still, the addition of durvalumab improved 3-year invasive disease-free survival from \u003cstrong\u003e76.9% to 84.9%\u003c\/strong\u003e and overall survival from \u003cstrong\u003e83.2% to 95.1%\u003c\/strong\u003e. Interestingly, the immunotherapy was not continued in the adjuvant phase. The authors caution that the study was not powered to detect a survival difference, so these results need further confirmation.\u003c\/p\u003e\n\n\u003cp\u003ePD-L1 expression (a protein measured on tumor cells) is an established predictive biomarker in the advanced (metastatic) setting, but it does not separate responders from non-responders in early disease. Both patients with PD-L1-positive and PD-L1-negative tumors benefited from the addition of immune checkpoint inhibitors. The benefit of immunotherapy in early disease appears independent of PD-L1 status, although PD-L1-positive tumors are more likely to respond.\u003c\/p\u003e\n\n\u003ch3\u003eThree Open Questions in TNBC\u003c\/h3\u003e\n\n\u003cp\u003eThe authors identify three major questions that future studies in the post-neoadjuvant setting must answer:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eWhat is the best backbone chemotherapy to combine with immunotherapy?\u003c\/li\u003e\n  \u003cli\u003eHow can capecitabine and olaparib be integrated with immune checkpoint inhibitors when residual disease is present after neoadjuvant chemotherapy?\u003c\/li\u003e\n  \u003cli\u003eIs it possible to de-escalate immunotherapy once pCR has been achieved?\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe first question matters because the chemotherapy regimen could influence how well the immunotherapy works. In the phase II TONIC trial, patients with advanced TNBC were randomised to two weeks of induction therapy with either cyclophosphamide, doxorubicin, cisplatin or irradiation, followed by nivolumab. Patients who received doxorubicin and cisplatin as induction showed the highest overall response rates: \u003cstrong\u003e35% and 23%\u003c\/strong\u003e respectively. Consistent with this, in the NeoTRIP trial, which tested adding atezolizumab to an anthracycline-free chemotherapy regimen in the neoadjuvant phase, no increase in pCR was observed. These effects may be subtle and hard to assess from indirect comparisons between trials. But the data suggest the choice of chemotherapy backbone could have a major impact on immunotherapy efficacy.\u003c\/p\u003e\n\n\u003cp\u003eFor the second question, no data are yet available in the early setting. In current practice, adjuvant treatment of patients with residual disease can be tailored according to residual cancer burden, overall recurrence risk and BRCA germline status:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIn patients at \u003cstrong\u003ehigh risk of recurrence\u003c\/strong\u003e, it may be appropriate to give adjuvant capecitabine if residual disease is present and to continue pembrolizumab if it was started during neoadjuvant treatment.\u003c\/li\u003e\n  \u003cli\u003eIn \u003cstrong\u003eBRCA-mutated patients\u003c\/strong\u003e, olaparib is recommended for one year if the risk of recurrence is high.\u003c\/li\u003e\n  \u003cli\u003eIn patients with \u003cstrong\u003elow residual cancer burden and low overall recurrence risk\u003c\/strong\u003e, continuing pembrolizumab alone could be a reasonable option if no immune-related side effects occurred during the neoadjuvant phase.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe unresolved question is whether a PARP inhibitor should be added to pembrolizumab when pembrolizumab is used in the neoadjuvant phase. The potential side effects of this combination need to be carefully weighed, as no robust data exist in the early setting yet.\u003c\/p\u003e\n\n\u003cp\u003eOn the third question, KEYNOTE-522 showed that adding pembrolizumab for patients who achieved pCR was associated with only a \u003cstrong\u003e2% improvement\u003c\/strong\u003e in 3-year event-free survival, whereas a \u003cstrong\u003e10% difference\u003c\/strong\u003e was observed in patients who did not achieve pCR. This has raised the question of whether adjuvant treatment could be reduced for patients who reach pCR with chemo-immunotherapy. However, in the absence of prospective evidence, pembrolizumab in adjuvant treatment should still be considered the standard therapy even in patients with pCR.\u003c\/p\u003e\n\n\u003ch2 id=\"her2\"\u003eHER2-Positive Breast Cancer: T-DM1 and Beyond\u003c\/h2\u003e\n\n\u003cp\u003eFor patients with HER2-positive breast cancer who have residual disease after neoadjuvant chemotherapy, the established post-neoadjuvant standard is \u003cstrong\u003eT-DM1 (trastuzumab emtansine)\u003c\/strong\u003e, an antibody-drug conjugate (a drug that links a chemotherapy payload to an antibody that seeks out HER2-positive cancer cells).\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eKATHERINE\u003c\/strong\u003e trial enrolled \u003cstrong\u003e1,486 patients\u003c\/strong\u003e with residual invasive disease after neoadjuvant treatment and compared T-DM1 with trastuzumab alone. Three-year invasive disease-free survival was \u003cstrong\u003e88.3% with T-DM1 versus 77.0% with trastuzumab\u003c\/strong\u003e (HR 0.50) — one of the largest treatment effects reported in this setting.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eExteNET\u003c\/strong\u003e trial tested extended adjuvant \u003cstrong\u003eneratinib\u003c\/strong\u003e (an oral HER2-targeted drug) versus placebo. In the overall population of \u003cstrong\u003e2,840 patients\u003c\/strong\u003e:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e5-year invasive disease-free survival: \u003cstrong\u003e90.8% versus 85.7%\u003c\/strong\u003e (HR 0.58).\u003c\/li\u003e\n  \u003cli\u003e8-year overall survival: \u003cstrong\u003e91.5% versus 89.4%\u003c\/strong\u003e (HR 0.79).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe benefit signal was strongest among the \u003cstrong\u003e1,334 patients with hormone receptor-positive disease who started neratinib within one year of finishing trastuzumab\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eMultiple ongoing trials are now pushing this field further. \u003cstrong\u003eDESTINY-Breast05\u003c\/strong\u003e compares the next-generation antibody-drug conjugate T-DXd (trastuzumab deruxtecan) with T-DM1 in patients with residual disease after neoadjuvant treatment, with invasive disease-free survival as the endpoint. \u003cstrong\u003eDESTINY-Breast11\u003c\/strong\u003e tests T-DXd in the neoadjuvant setting. \u003cstrong\u003eCompassHER2-RD\u003c\/strong\u003e adds tucatinib (an oral HER2 inhibitor) to T-DM1, while \u003cstrong\u003eAstefania\u003c\/strong\u003e combines T-DM1 with the immunotherapy atezolizumab.\u003c\/p\u003e\n\n\u003cp\u003eDe-escalation is also under study. \u003cstrong\u003eDECRESCENDO\u003c\/strong\u003e assigns treatment based on how much residual disease remains — patients with RCB 0 receive pertuzumab and trastuzumab, those with RCB 1 receive T-DM1, and those with RCB 2 or higher receive anthracycline-based chemotherapy followed by T-DM1. \u003cstrong\u003ePHERGAIN-2\u003c\/strong\u003e tests a chemotherapy-free, pCR-guided strategy. Other trials are testing the oral HER2 drug pyrotinib in the post-neoadjuvant setting (ATP and NCT04973319).\u003c\/p\u003e\n\n\u003ch2 id=\"hr\"\u003eHormone Receptor-Positive, HER2-Negative Breast Cancer: CDK 4\/6 Inhibitors\u003c\/h2\u003e\n\n\u003cp\u003eHormone receptor-positive, HER2-negative disease is the most common subtype, and its post-neoadjuvant options have expanded recently. The main drug class studied is the \u003cstrong\u003eCDK 4\/6 inhibitor\u003c\/strong\u003e — a drug that blocks two proteins (CDK 4 and CDK 6) that help cancer cells divide.\u003c\/p\u003e\n\n\u003cp\u003eTwo trials tested \u003cstrong\u003epalbociclib\u003c\/strong\u003e, and neither showed a clear benefit:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePALLAS\u003c\/strong\u003e (5,796 patients): palbociclib plus endocrine therapy versus endocrine therapy alone. 4-year invasive disease-free survival: \u003cstrong\u003e84.2% versus 84.5%\u003c\/strong\u003e (HR 0.96).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePENELOPE-B\u003c\/strong\u003e (1,250 patients): palbociclib versus placebo. 3-year invasive disease-free survival: \u003cstrong\u003e81.2% versus 77.7%\u003c\/strong\u003e (HR 0.93).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBy contrast, \u003cstrong\u003eabemaciclib\u003c\/strong\u003e — a different CDK 4\/6 inhibitor — did show benefit in the \u003cstrong\u003eMonarchE\u003c\/strong\u003e trial:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eOverall population (5,637 patients): 3-year invasive disease-free survival \u003cstrong\u003e88.8% with abemaciclib plus endocrine therapy versus 83.4% with endocrine therapy alone\u003c\/strong\u003e (HR 0.69); 3-year distant relapse-free survival \u003cstrong\u003e90.3% versus 86.1%\u003c\/strong\u003e (HR 0.68).\u003c\/li\u003e\n  \u003cli\u003ePatients who had received prior neoadjuvant chemotherapy (2,087 patients): 3-year invasive disease-free survival HR \u003cstrong\u003e0.69\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOlaparib also has a role in this subtype. In the hormone receptor-positive subgroup of the OlympiA trial (325 patients), 3-year invasive disease-free survival was \u003cstrong\u003e83.5% with olaparib versus 77.2% with placebo\u003c\/strong\u003e (HR 0.70).\u003c\/p\u003e\n\n\u003cp\u003eImmunotherapy is being explored here too. \u003cstrong\u003eCheckMate 7FL\u003c\/strong\u003e (NCT04109066) is testing nivolumab added to chemotherapy in high-risk early-stage disease, before and after surgery, with endocrine therapy afterwards. A parallel study (NCT03725059) evaluates pembrolizumab in the same population. The \u003cstrong\u003eRSBNAT\u003c\/strong\u003e trial stratifies treatment according to recurrence risk levels calculated from multiple genes.\u003c\/p\u003e\n\n\u003ch2 id=\"trials\"\u003eOngoing Clinical Trials: What Is Being Tested Now\u003c\/h2\u003e\n\n\u003cp\u003eThe review catalogues more than twenty ongoing phase II and phase III trials in the post-neoadjuvant setting. Highlights include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSASCIA\u003c\/strong\u003e (NCT04595565, phase III): compares the antibody-drug conjugate sacituzumab govitecan against the physician's choice of capecitabine or platinum-based chemotherapy in HER2-negative and TNBC patients with residual disease after neoadjuvant chemotherapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSWOG S1418\/BR006\u003c\/strong\u003e (NCT02954874, phase III): observation versus pembrolizumab in high-risk patients after neoadjuvant chemotherapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eA-Brave\u003c\/strong\u003e (NCT02926196, phase III): the immunotherapy avelumab versus observation in high-risk patients after neoadjuvant chemotherapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eASPRIA\u003c\/strong\u003e (NCT04434040, phase II): sacituzumab plus atezolizumab in patients with residual disease and detectable circulating tumor DNA after neoadjuvant chemotherapy. The endpoint is the rate of undetectable ctDNA after six cycles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBreastImmune03\u003c\/strong\u003e (NCT03818685, phase II): radiotherapy plus nivolumab and ipilimumab versus radiotherapy plus capecitabine in residual disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePERSEVERE\u003c\/strong\u003e (NCT04849364, phase II): assigns treatment by genomic pathway based on ctDNA results, using talazoparib, atezolizumab, inavolisib or capecitabine in various combinations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePHOENIX\u003c\/strong\u003e (NCT03740893, phase IIa): tests the ATR kinase inhibitor AZD6738, olaparib and durvalumab in residual disease, with change in the Ki67 proliferation index as the endpoint.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAPOLLO\u003c\/strong\u003e (NCT04501523, phase II): uses ctDNA to guide treatment with the anti-PD-1 antibody tislelizumab plus capecitabine, capecitabine alone, or follow-up.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOXEL\u003c\/strong\u003e (NCT03487666, phase II): nivolumab, capecitabine, or the combination.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZEST\u003c\/strong\u003e (NCT04915755, phase III): niraparib versus placebo in patients with ctDNA detected after surgery or adjuvant therapy, including those with BRCA mutations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCOGNITION-GUIDE\u003c\/strong\u003e (NCT05332561, phase II): a seven-arm \"umbrella\" trial using genomics-guided therapy — including immunotherapy, PARP inhibitors, antibody-drug conjugates, PI3K inhibitors, AKT inhibitors and anti-HER2 therapy — in high-risk patients with residual disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdditional smaller studies are testing atorvastatin with or without capecitabine, measuring circulating tumor cells at six months. Other studies are testing T-DM1 combined with a vaccine (TPIV100) and sargramostim. More studies are testing epirubicin or pirarubicin versus cyclophosphamide, and platinum-based chemotherapy versus capecitabine. Further studies are testing vitamin D supplementation in patients who are vitamin D deficient before and after neoadjuvant treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings at a Glance\u003c\/h2\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePatients who reach \u003cstrong\u003epCR\u003c\/strong\u003e after neoadjuvant chemotherapy have lower recurrence and death rates; those with residual disease are the target group for extra treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCapecitabine\u003c\/strong\u003e is approved for TNBC patients with residual disease after neoadjuvant chemotherapy. In the TNBC subgroup of CREATE-X, it cut 5-year disease-free survival risk by 42% (HR 0.58) and overall survival risk by 48% (HR 0.52).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eT-DM1\u003c\/strong\u003e is approved for HER2-positive patients with residual disease. KATHERINE showed 3-year invasive disease-free survival of 88.3% versus 77.0% (HR 0.50).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOlaparib\u003c\/strong\u003e for one year benefits patients with germline BRCA mutations, with a 3.4 percentage point absolute improvement in 4-year overall survival (89.8% vs 86.4%).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePembrolizumab\u003c\/strong\u003e improved pCR (64.8% vs 51.2%) and 36-month event-free survival (84.5% vs 76.8%) in high-risk early TNBC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbemaciclib\u003c\/strong\u003e improved 3-year invasive disease-free survival in hormone receptor-positive disease (88.8% vs 83.4%, HR 0.69), while \u003cstrong\u003epalbociclib\u003c\/strong\u003e did not.\u003c\/li\u003e\n  \u003cli\u003ePlatinum chemotherapy and genomic matching \u003cstrong\u003efailed\u003c\/strong\u003e to beat capecitabine or standard therapy in TNBC with residual disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe post-neoadjuvant setting has become one of the fastest-moving areas in breast cancer care. For patients, the practical meaning is direct: the amount of tumor left at surgery is now used to decide whether extra treatment is added.\u003c\/p\u003e\n\n\u003cp\u003eIf you have TNBC and tumor remains after pre-surgery chemotherapy, you may be offered capecitabine. If you carry a BRCA1 or BRCA2 mutation, one year of olaparib may be recommended. If you have HER2-positive disease with residual tumor, T-DM1 is the standard. If your cancer is hormone receptor-positive and HER2-negative with high-risk features such as positive lymph nodes, abemaciclib plus endocrine therapy may be discussed.\u003c\/p\u003e\n\n\u003cp\u003ePatients who achieve pCR face a different conversation. Their risk is lower, and treatment reduction (de-escalation) may be raised — but the review stresses caution. The management of a patient with pCR is multifactorial and requires multidisciplinary discussion. Removing too many treatment components could be harmful.\u003c\/p\u003e\n\n\u003cp\u003eThe review also highlights the growing role of biomarkers for tailoring decisions. These include Ki67, TILs, the RCB index, gene expression profiles, genetic alterations, and circulating tumor DNA — fragments of tumor DNA detectable in the blood. Several ongoing trials are designed specifically to use ctDNA to guide who receives more treatment and who can safely receive less.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Research Cannot Tell Us\u003c\/h2\u003e\n\n\u003cp\u003eSeveral important gaps remain.\u003c\/p\u003e\n\n\u003cp\u003eFirst, many of the immunotherapy survival results are immature. In IMpassion031, the authors state explicitly that the trial was not powered to evaluate event-free survival, disease-free survival or overall survival. No median values have been reached for those endpoints yet.\u003c\/p\u003e\n\n\u003cp\u003eSecond, some encouraging results come from studies not designed to prove a survival benefit. The Gepar-Nuevo findings came from a trial that did not meet its primary endpoint of improving pCR. The trial was not powered to detect a survival difference. The findings were improved 3-year invasive disease-free survival from 76.9% to 84.9% and overall survival from 83.2% to 95.1%. The authors call for further confirmation.\u003c\/p\u003e\n\n\u003cp\u003eThird, PD-L1 testing, which guides immunotherapy decisions in advanced disease, does not identify who will benefit in early disease. This makes patient selection harder.\u003c\/p\u003e\n\n\u003cp\u003eFourth, comparisons between trials are indirect. The TONIC and NeoTRIP observations about which chemotherapy backbone works best with immunotherapy come from different studies rather than a head-to-head comparison. The review notes that extremely large studies would be needed to answer this question definitively.\u003c\/p\u003e\n\n\u003cp\u003eFinally, for several key clinical questions — such as combining a PARP inhibitor with pembrolizumab — no robust data exist in the early setting. The review's authors also acknowledge that their review is based on literature and conference proceedings available up to 1 August 2022, so conclusions reflect the evidence at that time.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Practical Advice\u003c\/h2\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your residual disease status.\u003c\/strong\u003e Ask your oncology team whether you achieved pCR or whether residual disease was found, and what the RCB score was. This result drives the next treatment decision.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about germline genetic testing\u003c\/strong\u003e if you have TNBC or another high-risk feature, since BRCA1\/2 mutation status determines whether olaparib is an option.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss your subtype-specific post-neoadjuvant options:\u003c\/strong\u003e capecitabine for TNBC with residual disease, T-DM1 for HER2-positive residual disease, abemaciclib plus endocrine therapy for high-risk hormone receptor-positive disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk whether you are eligible for a clinical trial.\u003c\/strong\u003e More than twenty studies are actively recruiting, testing new drugs, combinations and ctDNA-guided strategies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect a multidisciplinary discussion\u003c\/strong\u003e if you achieved pCR, since the decision to reduce treatment is not straightforward and needs input from surgery, radiation oncology, pathology and medical oncology.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReport any immune-related side effects\u003c\/strong\u003e during immunotherapy, since these influence whether the drug can be continued after surgery.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat does it mean if I still have tumor left after chemotherapy before surgery?\u003c\/h3\u003e\n\u003cp\u003eCancer cells remaining in the tissue removed at surgery is called residual disease. Patients with residual disease have a higher risk of the cancer returning than those whose tumor disappeared completely. This is why extra treatment after surgery may be discussed. The amount of tumor left is now used to help decide whether more treatment is added.\u003c\/p\u003e\n\u003ch3\u003eWhat is a pathological complete response (pCR)?\u003c\/h3\u003e\n\u003cp\u003eA pathological complete response means no detectable invasive cancer cells were found in the tissue removed at surgery. Patients who reach pCR have a lower risk of the cancer returning. In a pooled analysis of 11,955 patients, those who achieved pCR after chemotherapy before surgery had better long-term survival than patients with leftover tumor.\u003c\/p\u003e\n\u003ch3\u003eWhat extra treatment might I be offered if I have triple-negative breast cancer with tumor left after pre-surgery chemotherapy?\u003c\/h3\u003e\n\u003cp\u003eCapecitabine, an oral chemotherapy drug, is now standard for triple-negative breast cancer patients with residual disease after chemotherapy before surgery. In the CREATE-X trial of 910 patients with HER2-negative disease, the triple-negative subgroup of 286 patients had better disease-free and overall survival with capecitabine than with no further treatment.\u003c\/p\u003e\n\u003ch3\u003eI have HER2-positive breast cancer and tumor remained at surgery. What is the standard extra treatment?\u003c\/h3\u003e\n\u003cp\u003eT-DM1 (trastuzumab emtansine) is the established treatment after surgery for HER2-positive patients with residual disease. In the KATHERINE trial of 1,486 patients, three-year invasive disease-free survival was 88.3% with T-DM1 versus 77.0% with trastuzumab alone. T-DM1 links a chemotherapy payload to an antibody that seeks out HER2-positive cancer cells.\u003c\/p\u003e\n\u003ch3\u003eDoes a BRCA mutation change my treatment options after surgery?\u003c\/h3\u003e\n\u003cp\u003eYes. If you carry an inherited BRCA1 or BRCA2 mutation, one year of the PARP inhibitor olaparib may be recommended when recurrence risk is high. In the OlympiA trial, four-year overall survival was 89.8% with olaparib versus 86.4% with placebo, an absolute improvement of 3.4 percentage points. Ask your team about germline genetic testing.\u003c\/p\u003e\n\u003ch3\u003eWhat does a hazard ratio below 1.0 mean in these trials?\u003c\/h3\u003e\n\u003cp\u003eA hazard ratio compares risk between two groups. A number below 1.0 means the treatment group did better. For example, a hazard ratio of 0.50 means the risk of an event was cut roughly in half. In the KATHERINE trial, the hazard ratio for invasive disease-free survival with T-DM1 versus trastuzumab was 0.50.\u003c\/p\u003e\n\u003ch3\u003eCan treatment after surgery be reduced if my tumor disappeared completely?\u003c\/h3\u003e\n\u003cp\u003eTreatment reduction may be discussed if you achieved pCR, because your risk is lower. However, the review stresses caution: managing a patient with pCR is multifactorial and needs multidisciplinary discussion, and removing too many treatment components could be harmful. In the absence of prospective evidence, continuing pembrolizumab after surgery is still considered standard even in patients with pCR.\u003c\/p\u003e\n\u003ch3\u003eIf I still have tumor left after pre-surgery chemotherapy for early breast cancer, when should I get a second opinion on my post-surgery treatment?\u003c\/h3\u003e\n\u003cp\u003eWhen residual disease remains at surgery, the next step depends on subtype and risk. The options are capecitabine for triple-negative disease, T-DM1 for HER2-positive disease, abemaciclib plus endocrine therapy for high-risk hormone receptor-positive disease, and one year of olaparib for germline BRCA mutations. Because these options differ and more than twenty trials are recruiting, a second opinion can help confirm your residual disease status, RCB score and germline testing. A second opinion can also clarify which additional treatment fits. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Published in \u003cem\u003eCancers\u003c\/em\u003e (MDPI), 2022, volume 14, article 5467. DOI: 10.3390\/cancers14215467. Published online 7 November 2022. This is an open-access article distributed under the Creative Commons Attribution (CC BY) license.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individual medical advice. Patients should discuss their own treatment options with their oncology team.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47560929083548,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/it\/products\/post-neoadjuvant-treatment-for-early-breast-cancer-what-happens-when-cancer-remains-after-chemotherapy","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}